Journal Scans
Negative Impact of Bone Metastasis on Outcome in Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Bone Metastases Adversely Impact Outcomes in RCC Treated With Sunitinib
B Beuselinck, S Oudard, O Rixe, P Wolter, A Blesius, J Ayllon, R Elaidi, P Schöffski, E Barrascout, A Morel, B Escudier, H Lang, J Zucman-Rossi, J Medioni
20100911
2010 Oct 11
Ann Oncol
Negative Impact of Bone Metastasis on Outcome in Clear-cell Renal Cell Carcinoma Treated With Sunitinib
Ann Oncol. 2010 Oct 11;21(11), B Beuselinck, S Oudard, O Rixe, P Wolter, A Blesius, J Ayllon, R Elaidi, P Schöffski, E Barrascout, A Morel, B Escudier, H Lang, J Zucman-Rossi, J Medioni
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Targeted agents rather than cytokines (interferon alpha or interleukin 2) are now standard first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Consequently, the predictive and prognostic factors for the disease that were developed for patients receiving cytokines need to be updated. Recent studies of targeted agents in mRCC suggest, for example, that elevated baseline neutrophil and platelet counts may predict shorter overall survival (OS). Another possible adverse factor...
